fda compounding restrictions bpc 157 BPC-157 just got voted in favor to be added to the 503A Bulk Drug Substances list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank FDA Compliance for Peptide Therapy

FDA Compliance for Peptide Therapy and BPC 157 Holt Law Big news for the peptide space., The FDA Pharmacy Compounding Advisory Committee recently voted eight to six in favor of allowing compounding pharmacies to produce BPC 157. Here is what you need to FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable)

SKU: 55542809124 · From vanierexcavation.com